Glenmark Pharmaceuticals launches ‘Digihaler’ – Feedback

Glenmark Pharmaceuticals has launched Digihaler, a Digital Dose Inhaler (DDI). This next-gen inhaler provides accurate digital dose counter along with low dose warning indicator to enable asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy. The development comes on the back of patients’ compliance being a challenge globally when it comes to chronic disease treatment.

Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India. It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *